Please ensure Javascript is enabled for purposes of website accessibility

What Really Mattered With Editas Medicine's Q1 Update

By Keith Speights - Updated May 5, 2021 at 5:01PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It wasn't the biotech's financial performance.

Editas Medicine (EDIT -1.49%) entered 2021 with tremendous momentum. That's definitely not the case anymore: Its shares are down more than 60% from their highs set in January.

The company announced its first-quarter results before the market opened on Wednesday. Investors pretty much yawned, with the biotech stock barely moving in early trading. Here are the highlights from Editas' Q1 update.

DNA molecule.

Image source: Getty Images.

By the numbers

Editas reported revenue in the first quarter of $6.5 million, up 14% year over year. This result beat the Wall Street consensus estimate of $5.77 million.

The company announced a Q1 net loss of $56.7 million, or $0.86 per share, based on generally accepted accounting principles (GAAP). In the prior-year period, Editas posted a GAAP net loss of $37.7 million, or $0.69 per share. The average analysts' estimate was for a net loss of $0.73 per share.

Editas ended the first quarter with cash, cash equivalents, and short-term investments of $723.2 million. This was an increase from the $511.8 million on hand as of Dec. 31, 2020.

Behind the numbers

Most of Editas' revenue in the first quarter stemmed from its collaboration with Bristol Myers Squibb in developing gene-editing cell therapies targeting cancer. The company's deteriorating bottom line resulted from increased spending on research and development and general and administrative expenses.

As is the case with most clinical-stage biotechs, though, Editas Medicine's Q1 financial performance didn't matter very much. Investors expected revenue would be minimal and the net loss would be relatively high.

There are two things that do matter for Editas, however: pipeline progress and cash position. Editas hasn't had much to report on the first front so far this year. Its cash position has improved thanks to a stock offering conducted in January. The downside to that offering was that it diluted the value of existing shares of the biotech.

Probably the biggest story for Editas in the first quarter was its executive upheaval. In February, James Mullen replaced Cynthia Collins as CEO. In its Q1 update, Editas also announced that Mark Shearman will join the company in June as its new chief scientific officer. Sherman will take the place of Charles Albright, who left Editas in January to pursue another opportunity.

Looking ahead

There are plenty of developments for investors to look forward to this year. Editas expects to report results from the first two cohorts of a phase 1/2 study evaluating EDIT-101 in treating rare genetic eye disease Leber congenital amaurosis type 10 (LCA10) by year-end.

Goldman Sachs analyst Madhu Kuma isn't optimistic about those results and thinks that Editas' share price could fall more than 40%. However, positive news from the early-stage study would almost certainly light a fire beneath the stock.

Editas also is on track to begin dosing patients by the end of the year in a phase 1/2 study evaluating EDIT-301 in treating sickle cell disease. The company plans to file for U.S. approval by late 2021 to begin a clinical study of the gene-editing therapy in treating another rare blood disorder, beta thalassemia.

Keith Speights owns shares of Bristol Myers Squibb and Editas Medicine. The Motley Fool owns shares of and recommends Bristol Myers Squibb and Editas Medicine. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Editas Medicine, Inc. Stock Quote
Editas Medicine, Inc.
EDIT
$19.13 (-1.49%) $0.29
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
BMY
$73.80 (2.33%) $1.68

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
377%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/08/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.